Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

23.58 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Recap: Beam Therapeutics Q2 Earnings
  Beam Therapeutics (NASDAQ:BEAM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses
The company didn't identify the reason behind the clinical hold in cancer treatment. 
Via Investor's Business Daily
BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Why Is Target (TGT) Stock in the Spotlight Today?
Target (TGT) stock is in the news today as investors react to a new note from Jefferies that gives the retail company flak. 
Via InvestorPlace
Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News
Beam Therapeutics (BEAM) stock is slipping on Monday after the U.S. Food and Drug Administration placed a clinical hold on one of its drugs. 
Via InvestorPlace
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Beam Therapeutics Shares Decline Following FDA's Clinical Hold On Leukemia Study
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Beam Therapeutics’ (NASDAQ: BEAM) Investigational New Drug (IND) application for the candidate BEAM-201 in the treatment of... 
Via Benzinga
Will a Recession Cause a Housing Crash in 2022?
For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage
Via Benzinga
Hold Pfizer Today With Catalysts for Further Growth Tomorrow
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives. 
Via MarketBeat
Exposures COVID-19 Product Safety
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol
This could offer an improvement over CRISPR, which requires cutting DNA. 
Via Investor's Business Daily
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics
Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ: 
Via Benzinga
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
The FDA's advisors recently backed Pfizer's Covid shot for young children. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock?
How the pandemic continued a transformation Pfizer says began years ago. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.